{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4195, 
        4202
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4908, 
        4915
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4134, 
        4143
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4203, 
        4212
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4916, 
        4925
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3975, 
        3998
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4000, 
        4016
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4462, 
        4482
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4484, 
        4492
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4037, 
        4064
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4066, 
        4076
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4018, 
        4022
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4079, 
        4083
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4148, 
        4152
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4402, 
        4406
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4435, 
        4439
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        3210, 
        3229
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4084, 
        4103
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4407, 
        4426
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3104, 
        3133
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3135, 
        3152
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4346, 
        4372
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4374, 
        4392
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4123, 
        4133
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4174, 
        4182
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4222, 
        4223
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4023, 
        4029
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4153, 
        4159
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4440, 
        4446
      ]
    }
  ], 
  "Positive Findings Phraseology (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4858, 
        4895
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4167, 
        4172
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4454, 
        4459
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        3154, 
        3156
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        3378, 
        3380
      ]
    }, 
    {
      "__agreement__": "FALSE POSITIVE", 
      "__annotator__": "Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4076, 
        4078
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4145, 
        4147
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4394, 
        4401
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4427, 
        4434
      ]
    }
  ], 
  "__text": "MSH|^~\\&|LABCORP-CORP|LABCORP^34D0655059^CLIA|Cancer Registry|State|201706010938|State006|ORU^R01|2017060107093839521000|P|2.3.1\nPID|1||^^^^SS^~11111111^^^^PI^|ALTERNATE ID|TEST^PATIENT^A||19500601|M||2054-5^Black or African American^CDC^^^|1234 Test Road^^ALBANY^NY^12201||^^^^^222^1234567|||||||\nORC|RE||111A1111111||||||||||||||||||Ordering Facility Name^^L|2222 W. Test Road^^Test^TX^77025|^^^^^111^1234567||\nOBR|1||111A1111111|^^^111111^Pathology Report^L|||201705301335|||||||20090115||Ordering Provider Name||||||20170530|||F|||||||\n\n\n\n\n\n\n\n\nSpecial 20 nuclei are counted and the ratio for 40 nuclei is recalculated. A HER2/CEN-17 ratio of 1.8-2.2 should be interpreted with caution. The ASCO/CAP guideline of 2013 (see below), includes additional criteria for determination of HER2 amplification or equivocal status based on the average HER2 signals/nucleus. Specimen handling: Tissue samples should be preserved in 10% neutral buffered formalin for 18-24 hours per FDA approved DAKO HER2 IQFISH pharmDX. Extended fixation time might increase the incubation time required for Pepsin digestion. ASCO/CAP guidelines requires fixation for a minimum of 6 and a maximum of 72 hours. The time from biopsy/excision to fixation in formalin (cold ischemic time) must be less than an hour. Time to fixation (cold ischemic time) greater than 1 hour should be interpreted with caution. HER2 testing, mainly HER2 by FISH, is particularly vulnerable since excessive cold ischemic time results in preferential loss of HER2 probe signals that may lead to false negative results. Intended Use: HER2 IQFISH pharmDX is indicated as an aid in the assessment of breast cancer patients for whom Herceptin? (Trastuzumab), PERJETATM (pertuzumab) or KADCYLATM (ado-trastuzumab emtansine) treatment is being considered. Results from HER2 IQFISH pharmDX are also used as an adjunct to the clinicopathologic information currently used for estimating prognosis in stage II, node-positive breast cancer patients. Reference: Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for HER2 Testing in Breast Cancer: ASCP/CAP Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1; 31(31):3997-4013. DAKO kit: Histology FISH Accessory kit code K5799 Disclaimer This Test was performed by Accupath Diagnostic Laboratories, Inc. at 5005 S 40th Street, Ste 1100, Phoenix, AZ, 85040. Integrated Oncology is a business unit of Accupath Diagnostic Laboratories, Inc., a wholly-owned subsidiary of Laboratory Corporation of America Holdings. This assay has not been validated on decalcified tissues. Results should be interpreted with caution if this specimen was decalcified given the likelihood of false negativity on decalcified specimens. Any image(s) that accompany this report is/are a representative image(s) only and should not be used to render a diagnosis. A copy of the complete report is on file. Professional services performed by Accupath Diagnostics Inc. at 5005 S. 40th St., Ste 1100, Phoenix, AZ 85040. Technical services performed by Accupath Diagnostics, Inc. at 5005 S. 40th St., Ste 1100, Phoenix, AZ 85040.\n\n\nPath report.gross observation\n\nGross description: A. Received in formalin labeled \"Kiranmai Sammani, left axillary lymph node,\" are three distinct needle cores of tan soft tissue ranging from 1.0 to 1.3 cm in length, which are submitted entirely in cassettes A1 through A3. B. Received in formalin labeled \"Kiranmai Sammani, left breast 4:00,\" are multiple needle cores of yellow-gray fibrofatty tissue measuring 1.7 x 0.6 x 0.2 cm in aggregate dimensions. The tissue is submitted in its entirety in cassettes B1 through B3. The cold ischemic time is less than 1 minute. The total formalin fixation time is 30 hours and 35 minutes. (DAC; 7/26/2017)\n\n\nPayment procedure\n\nCPT                            .88305 88305 88342 88341 88361\n\n\nPATHOLOGIST NAME\n\nElectronically signed: Pathologist name, Pathologist\n\n\nDiagnosis ICD code\n\nPathologist provided ICD-10:C77.3 C50.512\n\n\nPath report.relevant Hx\n\nClinical history: Left breast mass\n\n\nPath report.final diagnosis\n\nDiagnosis:A. Left axillary lymph node: - Lymph node with metastatic carcinoma. B. Left breast tissue 04:00: Invasive pleomorphic lobular carcinoma. - Grade 2.   - Architecture - 3   - Nuclei - 2   - Mitosis - 2 - Size of tumor in biopsy = 15 mm - No in situ component observed.\n\n\nPath report.site of origin\n\nMaterial submitted: Part: A Left axillary lymph node Part: B Left breast tissue 04:00\n\n\nPath report.comments\n\nComment:Breast prognostic marker studies pending with addendum to follow. Case shown to another pathologist with agreement. Dr. Kobbermann notified on 07/27/2017. B. Immunohistochemistry stains performed with controls with the following results in tumor cell population: E-cadherin: Negative to focally positive. High molecular weight cytokeratin: Positive-weak, focal. The findings corroborate the diagnosis of pleomorphic lobular carcinoma. (JCH:pit/sem; 7/28/2017)\n\n\n"
}